Navigation Links
Carmel Pharma Introduces PhaSeal Secondary Set (C60)
Date:10/31/2009

New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs

Columbus, OH (Vocus) October 31, 2009 -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, now offers the Secondary Set (C60) for safe, streamlined preparation and administration of IV bag infusions.

For safety and ease of use, the non-vented Secondary Set offers the following features:

 
  • Drip chamber (20 drops/mL)
  • Flow stop to facilitate priming of the Secondary Set from the bag prior to adding the drug
  • Universal spike with built-in PhaSeal Connector for safe, leakproof transfer of the drug to the IV bag
  • DEHP-free PVC tubing (40 in.)

For more information or to order, call 866-487-9250 or visit www.PhaSeal.com.

PhaSeal is more than a system for the safe handling of hazardous drugs. It's the only clinically proven closed-system drug transfer device (CSTD) available today and is validated by more than 10 independent, peer-reviewed, published clinical studies. Distinguished by prominent thought leaders as the "Gold Standard" in safe handling, PhaSeal's airtight Expansion Chamber and leakproof Double Membrane connections prevent exposure to hazardous drugs, including aerosols and vapors, and make it the only system that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definition of a true CSTD. Its streamlined design and universally-compatible components make the system easy to use from preparation and administration to waste disposal.

The PhaSeal System is manufactured by Carmel Pharma AB in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the United States since 1998 and implemented in more than 1000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children's in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; SwedishAmerican Hospital in Rockford, IL; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit www.phaseal.com or email info@carmelpharmausa.com. To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today's clinical thought leaders, please visit www.carmelpharmausa.com/media or contact Emily Frydendal at 614-318-2635 or emily.frydendal (at) carmelpharma (dot) com.

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3140064.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
2. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
3. China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009
4. Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse
5. WuXi PharmaTech Schedules Third-Quarter 2009 Earnings Release
6. 5 Steps to Pharmaceutical Marketing Happiness
7. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
8. Vestara Awarded MedAssets Supplier Contract For Automated Pharmaceutical Waste Management Solution
9. CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags
10. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
11. Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Carmel Pharma Introduces PhaSeal Secondary Set (C60) 
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: